Skip to main content

Roche to Exclusively Distribute Two DxS Cancer Companion Tests

NEW YORK (GenomeWeb News) – Roche said Monday that it will distribute two cancer mutation tests for the UK molecular diagnostics company DxS.
DxS makes companion diagnostics that can be used by oncologists to aid in the prognosis and development of treatments for cancer patients based on specific gene mutations, Roche said.
Roche will distribute the TheraScreen K-RAS Mutation Test, which detects seven mutations found in many cancer types and is used in colorectal cancer cases, through a worldwide, exclusive agreement.
The second test involved in the agreement, the TheraScreen EGFR 29 Mutation Test, detects mutations that correlate with responsiveness to EGFR tyrosine kinase inhibitors. This test may be used to help doctors choose lung cancer patients who are most likely to respond to treatment with EGFR tyrosine kinase inhibitors.
Roche has agreed to distribute this test exclusively to all global markets except the US, Canada, Mexico, and Hong Kong. Both of the companion tests have received European CE mark certification.
Financial terms of the agreement were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.